<DOC>
	<DOC>NCT00390858</DOC>
	<brief_summary>In this 4-year extension study the safety, efficacy and and pharmacokinetics of deferasirox in regularly transfused pediatric patients with β-thalassemia major was assessed. Patients who successfully completed the main 1 year trial (NCT00390858) were eligible to continue in this extension trial and receive chelation therapy with deferasirox for up to 4 years.</brief_summary>
	<brief_title>A 4-year Extension Study to Core 1-year Study of Iron Chelation Therapy With Deferasirox in β-thalassemia Major Pediatric Patients With Transfusional Iron Overload.</brief_title>
	<detailed_description />
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>Iron Overload</mesh_term>
	<mesh_term>beta-Thalassemia</mesh_term>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Deferasirox</mesh_term>
	<criteria>Completion of the planned 12month core trial, (NCT00390858). Female patients who have reached menarche and who were sexually active were to use doublebarrier contraception, oral contraceptive plus barrier contraceptive, or must have undergone clinically documented total hysterectomy and/or ovariectomy, or tubal ligation. Written informed consent obtained from the patient, and/or from the parent or legal guardian in accordance with the national legislation. Pregnant or breast feeding patients Patients with a history of noncompliance to medical regimens and patients who are considered by the investigator as potentially unreliable. Other protocoldefined exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>β-thalassemia major</keyword>
	<keyword>iron overload</keyword>
	<keyword>deferasirox</keyword>
	<keyword>pediatric rare anemia</keyword>
</DOC>